In this episode of our Life Sciences Insights podcast series, Sophie Wang and Madison Garrett discuss the Federal Circuit’s recent opinion in a patent infringement case between Salix Pharmaceuticals and Norwich Pharmaceuticals. The opinion arises out of Hatch-Waxman litigation concerning Norwich’s Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of Salix’s drug, rifaximin, marketed under the brand name Xifaxan®. Sophie and Madison discuss two main components of the opinion: (1) the use of a clinical trial protocol as prior art to render obvious a claim directed to a method of treatment with particular dosages, and whether that supports a reasonable expectation of success, and (2) the implications of a post-trial ANDA amendment with a section 8 carveout (a.k.a. skinny label) on an injunction order from the litigated case.

In this episode of our Litigation podcast series, Mike Gass, Chair of Choate’s securities litigation practice, and Kristen Perriello, a Principal in the Government Enforcement Group discuss the Supreme Court’s significant securities law decision in Macquarie Infrastructure Corp. v. Moab Partners. The decision focuses on whether Rule 10b-5(b) prohibits pure omissions or only half-truths. Mike and Kristen will provide an overview of the case and focus on the legal and practical takeaways arising from the decision.

In this episode of the Family Office Services Podcast Series, Choate Investment Advisors’ Erin Kerr and Alison Svizzero discuss how environmental, social, and governance (ESG) criteria are used by investors in evaluating companies, in addition to traditional fundamental analysis, to determine long-term performance. ESG has increased as an area of interest for investors over the past decade. Erin, who is a ChoateIA Chief Compliance Officer and the Chief Investment Officer, and Alison, a Portfolio Manager and the Head of Private Equity Investing, provide a comprehensive overview and debunk myths related to utilizing ESG as investment criteria.

In this episode of Choate’s Enforcement & Investigations Updates Podcast Series, Emily Hodge and Kristen Perriello discuss recent significant cases and decisions surrounding the False Claims Act - including legal and practical takeaways arising from the Supreme Court’s decisions in the SuperValu case and the Polansky qui tam case, as well as the string of differing decisions in the circuit courts relating to the causation element in False Claims Act cases premised on Anti-Kickback Statute violations. 

In this episode of Choate’s Life Sciences Insights Podcast Series, Sophie Wang, Stephanie Schonewald and Peter Flynn discuss the US Supreme Court’s opinion in Amgen v. Sanofi, one of this term’s most highly-watched cases for our clients concerning the law of enablement as it applies to patents directed to antibody therapeutics. Choate submitted an amicus brief in this case on behalf of Nobel Laureate and distinguished immunologist, Sir Gregory Winter, and a collection of other notable scientists, in support of Sanofi and Regeneron.

In this episode of the Family Office Services podcast, Tamer Alamuddin and Christine Wright of Choate Investment Advisors discuss the current U.S. debt ceiling, related political gridlock and fears about financial instability. In addition to giving an overall understanding of the debt ceiling and its historical framework, Tamer and Christine will share the potential investment implications related to the current situation in the U.S.

In this episode of our AdTech podcast series, Adam Bookbinder and Christine Savage of Choate and Jim Vint of Secretariat discuss how companies and other institutions can reduce legal risks surrounding the use of AdTech tools.

Please join us for a comprehensive live webinar discussing “Managing AdTech Risk When Capturing Sensitive Information” on Wednesday, April 12th at 12:00 p.m. Register here.

In the second episode of our AdTech Podcast Series, Adam Bookbinder and Christine Savage of Choate, and Jim Vint of Secretariat, discuss why AdTech risk should be on your priority list. This conversation will help listeners understand the actions being taken by the various regulators and class action attorneys around AdTech use by healthcare entities and others.

Please join us for a comprehensive live webinar discussing “Managing AdTech Risk When Capturing Sensitive Information” on Wednesday, April 12th at 12:00 p.m. Register here.